Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939047 | 0.87 | MEN1 (0.45) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL23329726 | 0.86 | AR (0.44) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL21743078 | 0.81 | CRBN (0.44) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL21743079 | 0.81 | CRBN (0.44) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL23330139 | 0.80 | CRBN (0.43) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL21723342 | 0.80 | CRBN (0.43) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL16013486 | 0.80 | CRBN (0.40) | CRBNARMAOASMN1; SMN2CTSK | |
| SCHEMBL24010681 | 0.78 | NPC1 (0.43) | ARSMN1; SMN2CTSKRAB9A | |
| SCHEMBL2665085 | 0.78 | CRBN (0.51) | CRBNARSMN1; SMN2CTSKMAPT | |
| SCHEMBL22557673 | 0.78 | ALDH1A1 (0.48) | CRBNMAOASMN1; SMN2CTSKMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000989-A1 | PYRROLO BENZODIAZEPINE DERIVATIVE, AND CONJUGATE, PREPARATION METHOD AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-01-02 | — | — | US | disclosed |
| WO-2023051814-A1 | PYRROLO BENZODIAZEPINE DERIVATIVE, AND CONJUGATE, PREPARATION METHOD AND USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| EP-3650448-A1 | INDOLE-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019007382-A1 | INDOLE-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2019-01-10 | — | — | WO | disclosed |
| EP-1899294-B1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2015-03-18 | — | — | EP | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2010087761-A1 | 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087761-A1 | 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-08-05 | — | — | WO | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1899294-A1 | THERAPEUTIC AGENTS | Merck Sharp & Dohme Limited (GB) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | CRBN 3677/4885AR 842/4885MAOA 790/4885 |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | CRBN 4710/4885AR 2283/4885MAOA 3675/4885 |
| US-20250000989-A1 | PYRROLO BENZODIAZEPINE DERIVATIVE, AND CONJUGATE, PREPARATION METHOD AND USE THEREOF | GABRA5, GABRA4, GABRA2 | CRBN 155/4885AR 992/4885MAOA 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.